| Literature DB >> 30990471 |
Sara Negri1, Enrico Oddone, Francesco Morandi, Cristina Sottani, Francesco Gardinali, Annalisa Lillo, Ornella Pastoris, Valerio Dacrema, Anna Losurdo, Elena Grignani, Danilo Cottica, Marcello Imbriani.
Abstract
BACKGROUND: Current Italian regulations and procedures for surface decontamination of antineoplastic drugs (ADs) are not clear. Therefore, most hospital pharmacies follow internal procedures as an interpretation of the recommended handling guidelines.Entities:
Mesh:
Substances:
Year: 2019 PMID: 30990471 PMCID: PMC7809970 DOI: 10.23749/mdl.v110i2.8001
Source DB: PubMed Journal: Med Lav ISSN: 0025-7818 Impact factor: 1.275
Main characteristics of tested reagents
| Reagent | Type of reagent | pH | Composition (technical data sheet information) |
| Hypo-Chlor® | disinfectant solution | 12.5 | Sodium hypochlorite 5.25% |
| Amuchina® 10% solution | disinfectant solution | 8.0-10.5 | Sodium hypochlorite 0.115% |
| Farmecol 70® | disinfectant solution | neutral | Trade name for Rubbing Alcohol (mainly denatured ethanol at 70% concentration) |
| Surfa’Safe SH® | cleaning and disinfection solution | 6 | Didecyl-dimethyl-ammonium Chloride and Polyhexamethylene Biguanide Hydrochloride up to 2.5% each |
| Incidin® OxyFoam | green detergent, disinfectant, medical aid | 2.2 | Hydrogen Peroxide (1.5%), Glycolic acid (<2.5%) and water (>95%). Registered Name by ECOLAB. The product is available all over the world. |
| Liquid Marseille soap | detergent | basic | PEG-(1-4) Myristic Ether Sulphate |
Figure 1Identification of the contamination zones on the BSC workbench. Spots illustrate the random deposition of 100 μL of each AD solution, to simulate the accidental loss of a droplet of preparation
Amount of antineoplastic drug (AD) deposited in each area and related theoretical concentration on the surface
| AD* | Concentration of solution (mg/ml) | Quantity deposited (μg) | Concentration on the surface (ng/cm2) |
| 5-FU | 50 | 5,000 | 12,500 |
| IP | 50 | 5,000 | 12,500 |
| CP | 20 | 2,000 | 5,000 |
| GEM | 100 | 10,000 | 25,000 |
* 5-FluoroUracil (5-FU), IPhosfamide (IP), CycloPhosphamide (CP) and Gemcitabine (GEM)
UPLC chromatographic gradient
| Time (minutes) | Flow rate (ml/min) | %A1 | %B1 | Curve |
| 0 | 0.45 | 99 | 1 | |
| 0.5 | 0.45 | 99 | 1 | 6 |
| 5 | 0.45 | 40 | 60 | 6 |
| 5.5 | 0.45 | 1 | 99 | 6 |
| 6.5 | 0.45 | 1 | 99 | 6 |
| 7.8 | 0.45 | 99 | 1 | 6 |
| 9 | 0.45 | 99 | 1 | 6 |
Precursor/production transitions used for quantitative analysis
| Precursorion | Production | CV | CE | |
| 5FU§ | 128.8 | 41.9 | 32 | 16 |
| 5FU-IS§ | 130.8 | 42.9 | 30 | 15 |
| 260.9 | 91.9 | 34 | 44 | |
| CP§ | 260.9 | 139.8 | 36 | 22 |
| GEM§ | 264.0 | 112.0 | 40 | 25 |
| IS§ | 325.0 | 154.0 | 38 | 40 |
§ 5-FluoroUracil (5-FU), IPhosfamide (IP), CycloPhosphamide (CP) and Gemcitabine (GEM)
Average recovery in the six repetitions
| mean | CV % | % recovery | |
| Concentration: 0.125 ng/cm2 each | |||
| GEM§ | 0.121 | 7.6 | 97 |
| CP§ | 0.114 | 6.4 | 91 |
| IP§ | 0.113 | 7.1 | 90 |
| 5FU§ | 0.104 | 13.3 | 83 |
| Concentration: 2.5 ng/cm2 each | |||
| GEM§ | 2.2 | 7.5 | 88 |
| CP§ | 2.4 | 3.6 | 95 |
| IP§ | 2.3 | 3.2 | 93 |
| 5FU§ | 2.6 | 2.7 | 102 |
§ 5-FluoroUracil (5-FU), IPhosfamide (IP), CycloPhosphamide (CP) and Gemcitabine (GEM)
Level of drugs on hood surfaces before the experiment (blank level)
| Position | GEM§ (ng/cm2) | CP§ (ng/cm2) | IP§ (ng/cm2) | 5-FU§ (ng/cm2) |
| 1A | 0.0017 | 0.0035 | <0.0003 | <0.01 |
| 1B | 0.0008 | 0.0029 | <0.0003 | <0.01 |
| 2A | <0.0008 | 0.0032 | <0.0003 | <0.01 |
| 2B | 0.0009 | 0.0215 | 0.0003 | <0.01 |
| 3A | 0.0020 | 0.0038 | <0.0003 | <0.01 |
| 3B | 0.0014 | 0.0098 | <0.0003 | <0.01 |
| 4A | 0.0013 | 0.0036 | <0.0003 | <0.01 |
| 4B | <0.0008 | 0.0084 | <0.0003 | <0.01 |
| 5A | 0.6320 | 0.0030 | - | <0.01 |
| 5B | 0.4413 | 0.0010 | - | <0.01 |
| 6A | 0.0478 | 0.0008 | - | <0.01 |
| 6B | 0.0378 | 0.0008 | - | <0.01 |
| 7A | 0.0445 | 0.0005 | - | <0.01 |
| 7B | 0.0298 | 0.0003 | - | <0.01 |
§ 5-FluoroUracil (5-FU), IPhosfamide (IP), CycloPhosphamide (CP) and Gemcitabine (GEM)
Residual concentrations of antineoplastic drugs (AD) in each area, after washing
| AD§ | Position | 5-FU* (ng/cm2) | IP (ng/cm2) | CP* (ng/cm2) | GEM* (ng/cm2) |
| Hypo-Chlor® + Farmecol 70® | 1A | 5.7 | 7.8 | 6.8 | 355.6 |
| 1B | 15.4 | 3.8 | 5.9 | 28.3 | |
| Amuchina® 10% | 2A | 1.8 | 10.2 | 4.9 | 88.9 |
| 2B | 2.2 | 5.9 | 4.6 | 182.0 | |
| Farmecol70® | 3A | 1070.4 | 634.5 | 254.8 | 4265.3 |
| 3B | 909.0 | 560.7 | 127.6 | 2843.5 | |
| Surfa’Safe SH® | 4A | 116.7 | 30.8 | 17.9 | 339.9 |
| 4B | 146.3 | 21.6 | 15.9 | 275.4 | |
| Amuchina® 10% + Farmecol 70® | 5A | 156.8 | . | 5.5 | 58.3 |
| 5B | 73.3 | . | 5.0 | 47.8 | |
| Incidin® Oxyfoam | 6A | 92.5 | . | 14.3 | 70.0 |
| 6B | 59.8 | . | 14.0 | 90.0 | |
| Marseille soap + Farmecol 70® | 7A | 34.3 | . | 6.3 | 34.5 |
| 7B | 43.0 | . | 5.3 | 27.3 | |
§ 5-FluoroUracil (5-FU), IPhosfamide (IP), CycloPhosphamide (CP) and Gemcitabine (GEM). IP was not available at the time of trial 2.
* BSC Italian limits (15): 1.5 ng/cm2, 3.6 ng/cm2, 8.2 ng/cm2 for 5_FU, CP and GEM, respectively
Efficiency (%) of washing procedures expressed as a percentage of anticancer drugs* removed from the surface
| Position | 5-FU | IP | CP | GEM | Average by position | Average for procedure | |
| Hypo-Chlor® + Farmecol 70® | 1A | 99.95 | 99.94 | 99.86 | 98.58 | 99.58 | 99.74 |
| 1B | 99.88 | 99.97 | 99.88 | 99.89 | 99.90 | ||
| Hypo-Chlor® | 2A | 99.99 | 99.92 | 99.90 | 99.64 | 99.86 | 99.82 |
| 2B | 99.98 | 99.95 | 99.91 | 99.27 | 99.78 | ||
| Farmecol70® | 3A | 91.44 | 94.92 | 94.90 | 82.94 | 91.05 | 92.31 |
| 3B | 92.73 | 95.51 | 97.45 | 88.63 | 93.58 | ||
| Surfa’Safe SH® | 4A | 99.07 | 99.75 | 99.64 | 98.64 | 99.28 | 99.29 |
| 4B | 98.83 | 99.83 | 99.68 | 98.90 | 99.31 | ||
| Amuchina® 10% + Farmecol 70® | 5A | 98.75 | . | 99.89 | 99.77 | 99.47 | 99.59 |
| 5B | 99.41 | . | 99.90 | 99.81 | 99.71 | ||
| Incidin® Oxyfoam | 6A | 99.26 | . | 99.72 | 99.72 | 99.57 | 99.60 |
| 6B | 99.52 | . | 99.72 | 99.64 | 99.63 | ||
| Marseille soap + Farmecol 70® | 7A | 99.73 | . | 99.88 | 99.86 | 99.82 | 99.82 |
| 7B | 99.66 | . | 99.90 | 99.89 | 99.81 | ||
* Anticancer Drugs: 5-FluoroUracil (5-FU), IPhosfamide (IP), CycloPhosphamide (CP) and Gemcitabine (GEM). IP was not available at the time of trial 2